Is CRSP a buy according to UQS?

UQS rates CRSP as Below Average at 33.1/100, driven primarily by a Risk score of 82.4 reflecting strong liquidity. Quality and Valuation both score 0.0, reflecting deep operating losses and negative profitability metrics. The composite score captures the fundamental tension between a well-funded balance sheet and the absence of current earnings power.

What is CRSP's PEG ratio and what does it mean?

CRSP carries a PEG ratio of 0.54, below the sector median of 0.89, which would typically suggest the stock is cheap relative to expected growth. However, the underlying earnings are negative, which limits the interpretive value of the PEG in this context. It reflects the scale of the forward growth estimate (4,108.4%) rather than a conventional earnings-based valuation signal.

Why might CRSP's UQS Score change?

The score is recalculated daily using TTM financial data and forward analyst estimates. For CRSP, the Quality and Valuation pillars (both 0.0) are most sensitive to changes: any shift toward positive operating margins or ROIC would lift Quality, while changes in forward revenue or earnings estimates would affect Valuation. Balance sheet deterioration would pressure the Risk score of 82.4.

CRSP

Healthcare

CRISPR Therapeutics AG · Biotechnology · $5B

UQS Score — Balanced Preset

32.8

Below Average

CRISPR Therapeutics AG scores 32.8/100 using the Balanced preset.

UQS vs Healthcare Sector

CRSP

32.8

Sector avg

32.4

Quality

Weak

Moat

Weak

Growth

Neutral

Risk

Strong

Valuation

Elevated

CRSP Price History

-53.0% over 5Y

Monthly close, adjusted for stock splits and dividend reinvestment.

Return Calculator

What if I invested in CRISPR Therapeutics AG?

If I had invested

Starting

Today it would be worth

$4,565

That's a -54.4% total return, or -14.5% annualized.

Based on CRISPR Therapeutics AG's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

Unlock Full CRSP Analysis

✓Detailed 6-pillar UQS breakdown with exact scores
✓All 29 metrics with sector-calibrated comparisons
✓6 investor presets (Buffett, Munger, Lynch, Wood, Graham, Balanced)
✓Watchlist tracking with score alerts
✓AI-generated investment perspectives across 6 preset views
✓Score history chart with change notifications

Analyze CRSP in Detail →

Pro Analysis

CRSP — Score History

Score changes· 2 most recent

Date	UQS	Quality	Moat	Growth	Risk	Value	Change
May 8, 2026	32.8	0.0	38.0	56.3	80.6	0.0	-0.3
Apr 2, 2026	33.1	0.0	38.0	56.3	82.4	0.0	—

CRSP — Pillar Breakdown

◆

Quality

— 0.0/100 (25%)

CRISPR Therapeutics AG currently shows below-average quality metrics, suggesting challenges with profitability.

Capital Efficiency (ROIC)Weak

How effectively capital is deployed to generate returns.

Return on EquityWeak

Profitability relative to shareholders' equity.

Operating ProfitabilityWeak

Ability to convert revenue into operating profit.

Net ProfitabilityWeak

Bottom-line profit as a share of revenue.

Cash GenerationWeak

Free cash flow relative to market value.

▲

Growth

— 56.3/100 (20%)

CRISPR Therapeutics AG demonstrates healthy growth trends across revenue and earnings.

Recent Revenue TrendWeak

Revenue trajectory over the last twelve months.

3Y Revenue CAGRStrong

Compound annual revenue growth rate over 3 years.

EPS GrowthWeak

Year-over-year earnings per share growth.

Forward Revenue OutlookStrong

Analyst consensus for future revenue growth.

◈

Risk

— 80.6/100 (15%)

CRISPR Therapeutics AG carries minimal financial risk with conservative leverage and strong solvency.

Financial LeverageStrong

Debt levels relative to earnings capacity.

Debt/EquityStrong

Total debt relative to shareholder equity.

Current RatioStrong

Short-term liquidity — ability to pay near-term obligations.

Interest CoverageWeak

Earnings capacity relative to interest payments.

●

Valuation

— 0.0/100 (15%)

CRISPR Therapeutics AG appears expensively valued relative to its fundamentals and growth prospects.

⬡

Moat

— 38/100 (25%)

CRISPR Therapeutics AG possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CRSP.

Score Composition

Quality

0.0×25%0.0

Growth

56.3×20%11.3

Risk

80.6×15%12.1

Valuation

0.0×15%0.0

Moat

38.0×25%9.5

Total

32.8Below Average

Financial Data

More Stock Analysis

How is the CRSP UQS Score Calculated?

The UQS (Unified Quality Score) for CRISPR Therapeutics AG is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses CRISPR Therapeutics AG's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether CRISPR Therapeutics AG is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.